Gri bio presents positive preclinical data from pipeline of nkt cell modulators in development for the treatment of systemic lupus erythematosus (sle)

Data presented at the 14 th international congress on autoimmunity encouraging preclinical data observed to date on par with ofev ® (nintedanib), a leading tyrosine kinase inhibitor with 2025 projected sales of $5 billion 1 company targeting ind filing for gri-0803 in q3 2024 with topline data expected q4 2024 la jolla, ca, may 21, 2024 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio,” “we,” “our,” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (nkt) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced vipin kumar chaturvedi, phd, chief scientific officer of gri bio presented encouraging preclinical data from the company's preclinical studies of type 2 nkt activating molecules, gri-0803 and gri-0124 at the 14 th international congress on autoimmunity held may 17-20, 2024 in ljubljana, slovenia (the congress). gri bio's second asset in development, gri-0803, is a novel activator of human type 2 nkt cells.
GRI Ratings Summary
GRI Quant Ranking